Verrica Pharmaceuticals VRCA will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Verrica Pharmaceuticals to report an earnings per share (EPS) of $-0.15.
The announcement from Verrica Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Historical Earnings Performance
In the previous earnings release, the company beat EPS by $0.06, leading to a 7.56% drop in the share price the following trading session.
Here's a look at Verrica Pharmaceuticals's past performance and the resulting price change:
Quarter | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
---|---|---|---|---|
EPS Estimate | -0.24 | -0.37 | -0.42 | -0.40 |
EPS Actual | -0.18 | -0.43 | -0.31 | -0.38 |
Price Change % | -8.0% | -44.0% | -7.000000000000001% | -1.0% |
Market Performance of Verrica Pharmaceuticals's Stock
Shares of Verrica Pharmaceuticals were trading at $0.44 as of May 09. Over the last 52-week period, shares are down 94.64%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.